68 results
DEFA14A
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
Additional proxy soliciting materials
9:14am
the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under … indications based on a comprehensive product assessment screen designed to identify indications where we believe ABP-450 can deliver significant value
8-K
AEON
AEON Biopharma Inc. - Ordinary Shares
3 May 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:27pm
of Financial Statements–Going Concern, the Company is required to make an assessment as of the date the restated financial statements are issued
8-K
EX-10.2
sa5 6ia1a76sm
19 Mar 24
Entry into a Material Definitive Agreement
4:33pm
8-K
btkn9h18dqj c9weyisq
16 Feb 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:10pm
8-K
EX-99.3
10tbc9g0esh4ejytlw85
19 Oct 23
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
4:23pm
8-K
EX-99.2
m0ge7
19 Oct 23
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
4:23pm
8-K/A
EX-99.8
r8yelk qsy3ms
11 Aug 23
Financial Statements and Exhibits
9:12pm
8-K/A
EX-99.9
s0d0 6velh
11 Aug 23
Financial Statements and Exhibits
9:12pm
8-K
EX-10.23
javt9f3n19iav0d43
27 Jul 23
Index to Financial Statements
5:28pm